Chemed Stock (NYSE:CHE), Trade Ideas

Chemed

Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

BELFB

BPMC

BPOP

CFFN

CNTA

COLB

EGBN

FFWM

FIBK

FLEX

HCSG

HSII

IBRX

ITGR

MBLY

MORN

NOVA

NTGR

OPRA

PHAR

TROX

U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session.

IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday

Price Target

Pre-Market Outlook

Analyst Ratings

AAPL

MDLZ

POWI

SAIA


	Truist Securities cut the price target for  Chevron Corporation (NYSE: CVX) from $193 to $190. Truist Securities analyst Neal Dingmann maintained a Hold rating. Chevron shares fell 1.2% to $166.54 in pre-market trading.


Saia To Rally Around 33%? Here Are 10 Other Analyst Forecasts For Monday

Media

BILI

On CNBC&#39;s &#34;Fast Money Halftime Report,&#34; the investment committee gave their final trades.

Decatur Capital Management CEO Degas Wright likes Chemed Corporation (NYSE: CHE).

&#39;Halftime Report&#39; Final Trades: CVS Health, Bilibili And More

Chemed Corp

CHENGHE ACQUISITION CO L A

CHINA EASTN AIRL LTD H by China Eastern Airlines Corp. Ltd.

China Eastern Airlines Corp Ltd

CHENGHE ACQUISITION CO UNIT 1 CL A & 1/2 WT EXP

The Chefs' Warehouse, Inc. - Common Stock

The Chefs' Warehouse Inc

Check-Cap Ltd

CHAMPION ELEC METALS INC by CHAMPION ELEC METALS INC.

Champion Electric Metals Inc

Cochlear Ltd

Tranchess - United States Dollar

WIIM

Chemed shares are trading lower after the company reported worse-than-expected Q1 financial results.

Guidance for 2024
Management reiterates its estimated full-year 2024 earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, and other discrete items, guidance range of $23.30 to $23.70. Management anticipates providing updated 2024 earnings guidance and related subsidiary operating metrics as part of the June 30, 2024 earnings press release.

Guidance

Chemed Sees FY24 EPS $23.30-$23.70 Vs $23.52 Est.

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) reported quarterly earnings of $5.20 per share which missed the analyst consensus estimate of $5.48 by 5.11 percent. This is a 7.88 percent increase over earnings of $4.82 per share from the same period last year. The company reported quarterly sales of $589.23 million which missed the analyst consensus estimate of $591.46 million by 0.38 percent. This is a 5.19 percent increase over sales of $560.16 million the same period last year.

Earnings

Earnings Misses

Chemed Q1 Adj $5.20 Misses $5.48 Estimate, Sales $589.23M Miss $591.46M Estimate

VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation ("Chemed") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>), announced it entered into an agreement on March 12, 2024 to acquire all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc. d/b/a/ Covenant Care ("Covenant") for an aggregate purchase price of $85 million. Covenant's hospice operations span the panhandle of Florida and Alabama, specifically including the Tallahassee, Marianna, Fort Walton Beach, Panama City, Crestview and Pensacola markets in Florida, and the Dothan and Mobile/Daphne markets in Alabama.
The transaction is structured as an asset purchase and parties will seek to close the transaction in the second quarter, subject to certain regulatory and other approvals.
Nick Westfall, Chairman and CEO of VITAS Healthcare, stated, "Covenant Care has a 44-year history of providing high-quality, patient-centered care across communities in Florida and Alabama. Being a similar long-standing, mission-focused provider, VITAS is looking forward to building upon their legacy by following our key values of putting patients, families, and our team members first. We are excited to welcome the Covenant Care team members who decide to join our VITAS family as we collectively move forward with making a difference in all the communities we have the privilege of serving. I would also like to thank the Covenant Care executive team and Board of Directors whose vision for how this transaction will help to fulfill both organizations' commitment to our missions led us to this successful announcement today."

VITAS, A Wholly-Owned Subsidiary Of Chemed To Buy Hospice Assets Of Covenant Care In Florida And Alabama For An Aggregate Purchase Price Of $85M

Chemed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) short percent of float has risen 3.02% since its last report. The company recently reported that it has 441 thousand shares sold short, which is 3.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Chemed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709574322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chemed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Chemed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Chemed's peer group average for short interest as a percentage of float is 10.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(CHE) - Analyzing Chemed's Short Interest

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and raises the price target from $604 to $712.

RBC Capital Maintains Outperform on Chemed, Raises Price Target to $712

Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and raises the price target from $625 to $650.

Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $650

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) reported quarterly earnings of $6.60 per share which beat the analyst consensus estimate of $6.25 by 5.6 percent. The company reported quarterly sales of $585.91 million which missed the analyst consensus estimate of $586.64 million by 0.12 percent. This is a 7.18 percent increase over sales of $546.65 million the same period last year.

Earnings Beats

Chemed Q4 2023 Adj EPS $6.60 Beats $6.25 Estimate, Sales $585.91M Miss $586.64M Estimate

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:15 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Chemed beat estimated earnings by 6.0%, reporting an EPS of $6.6 versus an estimate of $6.25.
Revenue was up $39.26 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.42 which was followed by a 9.0% increase in the share price the next day.
Here's a look at Chemed's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>4.90</td>
<td>5.09</td>
<td>4.81</td>
<td>5.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.32</td>
<td>4.71</td>
<td>4.82</td>
<td>5.39</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>558.41M</td>
<td>562.54M</td>
<td>548.78M</td>
<td>546.60M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>564.53M</td>
<td>553.82M</td>
<td>560.16M</td>
<td>546.65M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Chemed <a href="https://www.benzinga.com/quote/CHE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chemed: Q4 Earnings Insights

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

ALHC

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

FULC

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICCC

ICFI

ICUI

IMAX

IMXI

INGN

INSE

IPAR

JAMF

KIND

KURA

KVYO

LAZR

LGND

LGVN

Earnings Scheduled For February 27, 2024

Thursday marks the last chance for investors to receive the next dividend payout from Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>). 
<h3>What's Happening</h3>
The company announced on Friday that it would pay shareholders a quarterly dividend of 40 cents per share. On Friday, Chemed will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 40 cents lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Friday. Shareholders who own CHE as of the end of Thursday's session are eligible to receive the 40 cents dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on March 15, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
<a href="https://www.benzinga.com/stock//dividends">Click here</a> to find details on Chemed's previous dividends.
To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Dividends

Chemed: Dividend Insights

Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and raises the price target from $590 to $625.

Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $625

Chemed Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) – Today Chemed Corporation's Board of Directors has appointed Michael D. Witzeman as Chief Financial Officer, effective January 1, 2024, following the retirement of David P. Williams from that role.
Mr. Witzeman is currently Chemed's Vice President and Controller and serves as Chemed's principal accounting officer. He joined Chemed in 2005 following employment as Senior Manager of Assurance at Deloitte &amp; Touche LLP. He is a licensed CPA and a BBA in Accounting from the University of Cincinnati and an MBA from The Ohio State University.

Management

Chemed Corporation Announces The Appointment Of Michael D. Witzeman As CFO, Effective January 1, 2024, Following The Retirement Of David P. Williams From That Role

Insider Trades

Chemed Form4 Filing Shows CFO Patrick David Williams Sold 6,000 Shares At An Average Price Of $583.85 Per Share

Thursday marks the last chance for investors to receive the next dividend payout from Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>). 
<h3>What's Happening</h3>
The company announced on Friday that it would pay shareholders a quarterly dividend of 40 cents per share. On Friday, Chemed will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 40 cents lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Friday. Shareholders who own CHE as of the end of Thursday's session are eligible to receive the 40 cents dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on December 04, 2023. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
<a href="https://www.benzinga.com/stock//dividends">Click here</a> to find details on Chemed's previous dividends.
To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Chemed Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) announced today that the Board of Directors has formally authorized an additional $300 million for stock repurchase under Chemed's existing share repurchase program. These share repurchases will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility.

Buybacks

Chemed Corporation's Board Of Directors Authorizes An Additional $300M For Stock Repurchase

Chemed Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) – After more than three decades, Executive Vice President and Chief Financial Officer David P. Williams has announced that he will retire as Chemed's Chief Financial Officer as of December 31, 2023, but Mr. Williams will continue to work with Chemed for the transition period and beyond in providing his guidance and the benefit of his expertise to the executive team and the Board of Directors.
Throughout his career, David helped lead Chemed and its subsidiaries through unprecedented economic growth.
"It has been a privilege to work with David as an integral part of our management team for these last three decades," said Chemed Chief Executive Officer, Kevin McNamara. "David has done a fantastic job building and leading our financial organization and is leaving it very well-positioned to move forward."
David joined Chemed in 1990 as Vice President of Finance for The Omnia Group, a former subsidiary engaged in the manufacture and distribution of medical and dental products, and has served in a number of other roles with Chemed and its subsidiaries, including Roto-Rooter Management Company, since that time. In March 2004, the Chemed Board of Directors elected Mr. Williams a Vice President and the Chief Financial Officer of Chemed. In August 2007, he was named an Executive Vice President of Chemed, while retaining his title of CFO.

Chemed Corporation Announces The Retirement Of CFO David P. Williams On December 31, 2023

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and raises the price target from $576 to $604.

RBC Capital Maintains Outperform on Chemed, Raises Price Target to $604

Nicholas M. Westfall, Executive Vice President at Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>), reported a large acquisition of company stock options on October 26, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000019584/000120919123053619//Archives/edgar/data/19584/000120919123053619/0001209191-23-053619-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Westfall, Executive Vice President at Chemed, a company in the Health Care sector, was just awarded stock options worth 14,406 shares of CHE. The options give Westfall the right to buy the company's stock at $509.46 per share.
Chemed shares are trading down 0.87% at $549.43 at the time of this writing on Friday morning. Since the current price is $549.43, this makes Westfall's 14,406 shares worth $7,915,160.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000019584">Check Out The Full List Of Chemed's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chemed Executive Vice President Awarded $7.92M Worth of Stock Options

Brian C Judkins, VP and Chief Legal Officer at Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>), reported a large acquisition of company stock options on October 26, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000019584/000120919123053633//Archives/edgar/data/19584/000120919123053633/0001209191-23-053633-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Judkins, VP and Chief Legal Officer at Chemed, a company in the Health Care sector, was just awarded stock options worth 9,664 shares of CHE. The options give Judkins the right to buy the company's stock at $509.46 per share.
Chemed shares are trading down 0.87% at $549.43 at the time of this writing on Friday morning. Since the current price is $549.43, this makes Judkins's 9,664 shares worth $5,309,739.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000019584">Check Out The Full List Of Chemed's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chemed VP and Chief Legal Officer Awarded $5.31M Worth of Stock Options

VITAS Healthcare to acquire hospice assets of Covenant Care in Florida and Alabama

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Chemed (CHE – Research Report), Ionis Pharmaceutical...

Analysts Offer Insights on Healthcare Companies: Chemed (CHE), Ionis Pharmaceuticals (IONS) and Arcellx Inc (ACLX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Chemed (CHE – Research Report) and Alkermes (ALKS ...

Analysts Conflicted on These Healthcare Names: Chemed (CHE) and Alkermes (ALKS)

Additions and deletions of Oppenheimer's OPCO Trifecta

Chemed 2024 Earnings Preview

Chemed Non-GAAP EPS of $5.20 misses by $0.28, revenue of $589.2M misses by $1.9M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemed (NYSE:<a href="https://investorplace.com/stock-quotes/che-stock-quote/">CHE</a>) just reported results for the first quarter of 2024.<ul><li>Chemed reported earnings per share of $5.20. This was below the analyst estimate for EPS of $5.48.</li><li>The company reported revenue of $589.23 million.</li><li>This was 0.38% worse than the analyst estimate for revenue of $591.46 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/che-stock-earnings-chemed-for-q1-of-2024/">CHE Stock Earnings: Chemed Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CHE Stock Earnings: Chemed Misses EPS, Misses Revenue for Q1 2024

Analysts have been eager to weigh in on the Healthcare sector with new ratings on SI-Bone (SIBN – Research Report), Conmed (CNMD – Research Report)...

Analysts' Opinions Are Mixed on These Healthcare Stocks: SI-Bone (SIBN), Conmed (CNMD) and Chemed (CHE)

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed (CHE – Research Report) today and set a price target of $650.00. The compa...